Nemucore Medical Innovations, Inc.

Nemucore Medical Innovations, Inc.

Fighting deadly leukemia by developing a new targeted therapy & diagnostic

Print
View on Wefunder
Security Type
SAFE
Location
Wellesley, MA
Offering Date
June 30, 2018
Expected Close Date
September 28, 2018
Target Raise
$150.00K
Deal Notes
  • Future Equity (SAFE)
  • $20M valuation cap
  • 15% discount

Company Description

Chemotherapy, the standard cancer treatment, is largely prescribed by informed guesses. Because this inaccurate method kills both cancerous and healthy cells, patients suffer from nasty side effects and don't usually get a drug that works for them the first time, if they get one that works at all. We're developing a targeted therapy for a highly lethal leukemia and a diagnostic to determine which patients will respond well to the drug. We're about to start Phase 1b/2 of clinical trials.

Perks

$250+ Monthly updates on our progress, invitation to quarterly webcasts, and a spot on our investor wall of fame.

Key Deal Facts

Raised $7 million from National Cancer Institute and foundation grants
100+ years of biopharmaceutical experience in the executive leadership team. 
Leading experts at Memorial Sloan Kettering and Moffitt Cancer Centers are set to perform our clinical trial
Over 57 investors

Use of Proceeds

  • Drug finish, packaging and labeling
  • Clinical trials, regulatory and diagnostic
  • Manufacturing additional NMI-900
  • Licensing fees
  • Operations and administration

Management Team / Advisory Board Bios

Tim Coleman
Founder and CEO
Anti-cancer Crusader! Principal Investigator for NMI's 6 grants. PhD -Biochemistry, MBA, Marathoner

Barbara Davis
Chief Sceintific Officer
Dr. Davis is certified as a Diplomate, American College of Veterinary Pathologists and has over 20 years of research experience in female endocrine and reproductive pathology and cancers.

William "Sandy" White
COO
William S. White is the former CEO of Icon Bioscience and has over 25 years of pharma industry experience, including executive leadership, global development/licensing, R&D and commercialization.

Dave Williams
Senior VP, Operations
Dave has over 25 years of experience in cGMP large and small molecule manufacturing operations, process development/scale-up, facility design and construction, and R&D.

Allison B. Morse
Director of Clinical Affairs
Allison has more than 15 years of experience caring for women with cancer throughout the course of their disease. She has a Master’s in Public Health and a Master’s of Science in Nursing.

Deal Notes

  • Future Equity (SAFE)
  • $20M valuation cap
  • 15% discount
Amount Raised : $88,943
Reveal the Score by Voting
＿
Additional ratings from other users are needed to determine a viable CrowdScore for this deal.
The "CrowdScore" for this deal is determined by user ratings and other factors using our proprietary algorithm.
ⓘ
The overall viability and scalability of the business concept as well as the ability to drive the concept to profitability over time.
Business Idea
ⓘ
The progress made thus far in demonstrating that the business has viability, a customer base or other business traction.
Business Traction
ⓘ
The experience of the management team in running, scaling and/or exiting a business that required similar skills to execute the business plan.
Management Team
ⓘ
The value of the company compared to similar companies raising money from investors.
Valuation

Security Description

A SAFE is an agreement between you—the investor—and the company in which the company promises to give you a future equity stake based on the amount you invested. It also involves some kind of a triggering event that must take place in order for you to get your future equity stake. Be careful as you may only get equity if a particular event is triggered.

Research Reports

No reports have been submitted

Become a Reporter
Read Our Research Disclaimer

0 Comments

Post Comment